NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, October 25th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.54%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.1% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's management believes its shares are undervalued.

Allergan plc (NYSE:AGN) posted its quarterly earnings data on Tuesday, November, 5th. The company reported $4.25 EPS for the quarter, meeting analysts' consensus estimates of $4.25. The firm earned $4.03 billion during the quarter, compared to analysts' expectations of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $4.25 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided EPS guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 Wall Street analysts have issued 1-year price objectives for Allergan's stock. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's share price to reach $176.63 in the next year. This suggests that the stock has a possible downside of 8.0%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 17 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Headlines about AGN stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Allergan.

Allergan saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 14,580,000 shares, an increase of 19.2% from the December 15th total of 12,230,000 shares. Based on an average trading volume of 2,220,000 shares, the short-interest ratio is currently 6.6 days. Approximately 4.5% of the company's stock are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a number of of retail and institutional investors. Top institutional investors include Calamos Advisors LLC (0.11%), Metropolis Capital Ltd (0.06%), Vertex One Asset Management Inc. (0.05%), Advisors Capital Management LLC (0.04%), Nisa Investment Advisors LLC (0.03%) and Commerzbank Aktiengesellschaft FI (0.03%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, United Services Automobile Association, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Neville Rodie & Shaw Inc., State of Alaska Department of Revenue, Bowling Portfolio Management LLC and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Syquant Capital Sas, Calamos Advisors LLC, Metropolis Capital Ltd, Vertex One Asset Management Inc., Moon Capital Management LLC, Modus Advisors LLC, Legacy Private Trust Co. and Wealthfront Advisers LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $192.08.

Allergan has a market capitalization of $63.06 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]